MarketBeat
07 Jun 2026, 21:06 UTC · 15w ago
Verdict
Headline takes no side. We score CGON +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
Cretostimogene showed a 76% complete response rate in the BCG-unresponsive carcinoma in situ cohort, with 90% of patients maintaining that response from month 12 to 24.
More positive than 99% of claims this week
CG Oncology has reported zero Grade 3 adverse events to date for cretostimogene.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 92% of claims this week
The company has submitted clinical and non-clinical BLA modules, with the final manufacturing module expected by the end of this year.
More positive than 85% of claims this week
Data from the PIVOT-006 trial in intermediate-risk non-muscle invasive bladder cancer could be available in the coming months.
More positive than 77% of claims this week
The current manufacturing process is sufficient for commercial launch and can yield up to 50,000 vials annually.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The company reported high complete response rates, zero Grade 3 adverse events, and is progressing through BLA submissions.
More negative than 68% of ticker scores this week
Mentioned as a competitor with products (Balversa, TAR-200) that CG Oncology claims to differentiate from via a better mechanism and tolerability.
More negative than 68% of ticker scores this week
Mentioned as a competitor with an existing product (Keytruda) that CG Oncology claims to differentiate from via a better mechanism and tolerability.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
3h ago
More positive than 56% of relationship scores this week
[mutual] CG Oncology's cretostimogene competes with Merck's KEYTRUDA in the bladder cancer market.
+44.7%
Price agrees with the score
$77.74 vs $53.72 close before publication (Jun 5) · not market-adjusted
CGON chart →
